GENITAL VITILIGO FOLLOWING USE OF IMIQUIMOD 5% CREAM

Imiquimod is a small molecule with adjuvant pro-inflammatory effects that can be topically delivered as a cream for treating external genital and perianal warts. In our report, two Chinese males at the ages of 25 and 22 years were treated with imiquimod 5% cream for recurrent condyloma accuminatum,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ruzhi, Zhu, Wenyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications 2011
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132920/
https://www.ncbi.nlm.nih.gov/pubmed/21772604
http://dx.doi.org/10.4103/0019-5154.82501
_version_ 1782207886979497984
author Zhang, Ruzhi
Zhu, Wenyuan
author_facet Zhang, Ruzhi
Zhu, Wenyuan
author_sort Zhang, Ruzhi
collection PubMed
description Imiquimod is a small molecule with adjuvant pro-inflammatory effects that can be topically delivered as a cream for treating external genital and perianal warts. In our report, two Chinese males at the ages of 25 and 22 years were treated with imiquimod 5% cream for recurrent condyloma accuminatum, three times per week for 18 and 12. weeks, respectively. Depigmentation were noted and gradually enlarged in the treated areas after the two patients discontinued imiquimod. Therefore, clinicians should be made aware of the possible pigmentary changes associated with application of this cream.
format Online
Article
Text
id pubmed-3132920
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Medknow Publications
record_format MEDLINE/PubMed
spelling pubmed-31329202011-07-19 GENITAL VITILIGO FOLLOWING USE OF IMIQUIMOD 5% CREAM Zhang, Ruzhi Zhu, Wenyuan Indian J Dermatol Case Report Imiquimod is a small molecule with adjuvant pro-inflammatory effects that can be topically delivered as a cream for treating external genital and perianal warts. In our report, two Chinese males at the ages of 25 and 22 years were treated with imiquimod 5% cream for recurrent condyloma accuminatum, three times per week for 18 and 12. weeks, respectively. Depigmentation were noted and gradually enlarged in the treated areas after the two patients discontinued imiquimod. Therefore, clinicians should be made aware of the possible pigmentary changes associated with application of this cream. Medknow Publications 2011 /pmc/articles/PMC3132920/ /pubmed/21772604 http://dx.doi.org/10.4103/0019-5154.82501 Text en © Indian Journal of Dermatology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Zhang, Ruzhi
Zhu, Wenyuan
GENITAL VITILIGO FOLLOWING USE OF IMIQUIMOD 5% CREAM
title GENITAL VITILIGO FOLLOWING USE OF IMIQUIMOD 5% CREAM
title_full GENITAL VITILIGO FOLLOWING USE OF IMIQUIMOD 5% CREAM
title_fullStr GENITAL VITILIGO FOLLOWING USE OF IMIQUIMOD 5% CREAM
title_full_unstemmed GENITAL VITILIGO FOLLOWING USE OF IMIQUIMOD 5% CREAM
title_short GENITAL VITILIGO FOLLOWING USE OF IMIQUIMOD 5% CREAM
title_sort genital vitiligo following use of imiquimod 5% cream
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3132920/
https://www.ncbi.nlm.nih.gov/pubmed/21772604
http://dx.doi.org/10.4103/0019-5154.82501
work_keys_str_mv AT zhangruzhi genitalvitiligofollowinguseofimiquimod5cream
AT zhuwenyuan genitalvitiligofollowinguseofimiquimod5cream

Ejemplares similares